Mankind Pharma Ltd

Mankind Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Mankind Pharma Ltd

₹ 2,469 1.56%
11 May - close price
mankindpharma.com BSE: 543904 NSE: MANKIND
About

Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]

Key Points

Leadership[1]
- #1 Rank in Prescriptions over the last 8 yrs.
- #2 Rank by volume & #4 Rank by value in IPM
- 4 Consumer healthcare brands ranked #1 in their categories.

Website BSE NSE
  • Market Cap ₹ 1,02,072 Cr.
  • Current Price ₹ 2,469
  • High / Low ₹ 2,727 / 1,910
  • Stock P/E 57.8
  • Book Value ₹ 376
  • Dividend Yield 0.04 %
  • ROCE 15.0 %
  • ROE 13.9 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Promoter holding has decreased over last 3 years: -3.84%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty 500

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
1,936 1,872 2,092 2,260 2,209 2,007 2,413 2,544 2,414 2,127 2,541 2,609 2,633
1,563 1,491 1,594 1,662 1,636 1,482 1,837 1,781 1,668 1,650 1,868 1,916 1,854
Operating Profit 374 381 498 598 573 526 576 763 746 477 673 693 778
OPM % 19% 20% 24% 26% 26% 26% 24% 30% 31% 22% 26% 27% 30%
32 42 87 84 92 109 125 139 70 219 64 78 -27
Interest 9 1 2 4 4 4 7 3 200 162 147 147 138
Depreciation 71 67 69 77 90 87 91 90 91 105 97 99 108
Profit before tax 326 355 514 601 571 543 603 810 525 429 494 525 505
Tax % 24% 21% 20% 21% 15% 14% 16% 20% 22% 11% 16% 13% 11%
249 281 409 473 487 468 506 645 412 382 413 459 449
EPS in Rs 6.21 7.01 10.22 11.80 12.16 11.68 12.62 16.11 9.99 9.27 10.00 11.12 10.89
Raw PDF
Upcoming result date: 19 May 2026

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
3,918 3,829 4,794 5,530 7,486 8,127 8,629 9,498 9,909
3,141 3,124 3,550 4,151 5,644 6,429 6,358 6,930 7,288
Operating Profit 778 705 1,244 1,379 1,842 1,698 2,272 2,567 2,621
OPM % 20% 18% 26% 25% 25% 21% 26% 27% 26%
209 64 94 148 200 163 369 550 334
Interest 18 40 11 8 48 28 17 372 595
Depreciation 28 38 62 78 123 270 335 378 409
Profit before tax 941 691 1,265 1,440 1,871 1,563 2,289 2,367 1,952
Tax % 26% 26% 24% 25% 26% 20% 18% 18%
694 514 958 1,084 1,389 1,248 1,876 1,945 1,704
EPS in Rs 17.33 12.83 23.92 27.07 34.68 31.16 46.84 47.15 41.28
Dividend Payout % 0% 0% 32% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 15%
3 Years: 8%
TTM: 6%
Compounded Profit Growth
10 Years: %
5 Years: 12%
3 Years: 8%
TTM: -9%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 21%
1 Year: 3%
Return on Equity
10 Years: %
5 Years: 19%
3 Years: 17%
Last Year: 14%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 40 40 40 40 40 40 40 41 41
Reserves 2,957 3,025 3,611 4,694 6,500 7,744 9,663 14,599 15,469
360 190 3 101 688 5 24 7,254 7,248
652 596 877 1,045 1,710 1,583 1,790 1,934 2,104
Total Liabilities 4,009 3,851 4,531 5,880 8,939 9,371 11,516 23,828 24,862
534 778 945 987 2,927 3,142 3,552 3,471 3,393
CWIP 322 211 148 166 387 495 209 207 248
Investments 1,402 1,698 1,784 2,397 2,526 3,102 4,215 16,683 17,611
1,751 1,164 1,655 2,330 3,100 2,632 3,540 3,467 3,610
Total Assets 4,009 3,851 4,531 5,880 8,939 9,371 11,516 23,828 24,862

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
540 537 960 1,022 821 1,799 1,736 2,322
-516 -306 -396 -1,127 -1,360 -1,041 -1,665 -12,179
8 -240 -559 89 579 -710 -5 9,845
Net Cash Flow 31 -9 5 -16 40 48 66 -11
Free Cash Flow 309 371 795 830 -1,360 1,219 1,456 1,969
CFO/OP 102% 111% 99% 103% 70% 123% 95% 109%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 23 13 32 24 23 22 33 34
Inventory Days 120 126 124 169 183 132 160 153
Days Payable 115 101 113 122 133 103 75 79
Cash Conversion Cycle 27 38 43 72 73 52 118 108
Working Capital Days 95 44 41 42 26 40 55 -48
ROCE % 22% 36% 33% 30% 21% 24% 15%

Insights

In beta
Mar 2012 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Market Share by Value in IPM
%

Log in to view insights

Please log in to see hidden values.

Login
Volume Rank in IPM
Rank
Chronic Share in Total Portfolio (Ex-BSV)
%
Doctor Coverage
Number (Lakh)
Field Force Strength
Number
Mankind PCPM (Per Candidate Per Month)
INR Lakhs
Prescription Share
%
Number of Stockists
Number
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
76.50% 76.50% 76.50% 74.88% 74.87% 74.87% 72.71% 72.70% 72.67% 72.67% 72.66% 72.66%
4.18% 4.18% 6.74% 9.87% 11.58% 12.37% 13.34% 12.92% 13.07% 12.83% 11.34% 10.24%
4.65% 4.56% 9.78% 11.14% 9.94% 9.91% 11.05% 11.47% 11.50% 11.91% 13.26% 14.46%
14.67% 14.76% 6.97% 4.10% 3.61% 2.86% 2.89% 2.89% 2.75% 2.57% 2.75% 2.63%
No. of Shareholders 1,31,9181,34,7311,27,4491,35,1161,53,4501,63,8541,71,2811,80,5971,79,5491,70,3471,77,5391,77,606

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls